The Record - for physicians and other health care providers to share with their office staffs

Forward to a friend  |  Subscribe  |  The Record Archive  |  Contacts  |  bcbsm.com  |  Print entire issue

November 2016

All Providers

Blue Cross customers can opt for reference-based benefit designs

As part of our ongoing commitment to helping our customers and members better manage the cost of their health care, Blue Cross Blue Shield of Michigan is launching reference-based benefit designs.

These benefit designs, sometimes referred to as RBB, can be chosen by customers to supplement their current plans. They encourage members to gain as much information about certain services as possible, allowing them to take a more active role in their health care decisions.

Jan. 1, 2017, is the start date for the first customer group that has chosen this new option.
Here’s how it works:

  1. Employers select certain services and “reference prices” for those services. These prices are the costs established for an episode of care based on claims data received by Blue Cross from their providers.
  2. Information about these services and reference prices is shared with the employees of a particular group (the Blue Cross member).
  3. When members need a service that is selected for RBB, they’ll use a vendor tool that helps them understand the cost involved and then go to a health care provider for the service.
  4. Health care providers charge for the service the same way they do today.
  5. Blue Cross pays up to a certain amount for the service.
  6. If the health care provider offers the service at or below the reference price, Blue Cross pays the allowed amount plus any member liability.
  7. If the health care provider charges an amount that exceeds the reference price, the member is responsible for the difference between the selected reference price and additional amount, plus any existing liability.

It’s important to note that RBB doesn’t modify rates or change the amount that health care providers charge for their services. Health care providers can expect to receive contracted rates on all procedures. It does, however, affect member cost share.

Example: If a member has a reference cost of $500 for an MRI of the spine and the allowable amount is $700, then Blue Cross pays up to $500 for the procedure and the member is responsible for $200.

Members with RBB will know the amount they owe by using consumer transparency tools that are part of the RBB. Providers will know the member cost share by checking web-DENIS.

As customer groups choose RBB for their members, we’ll include this information in the monthly billing chart in The Record, and we’ll also include the information in Benefit Explainer. In addition, we’ll post an RBB presentation on web-DENIS in mid-November and provide you with more details in the December Record.

Frequently asked questions about RBB

How are reference costs established?

Reference costs are established for a specific episode of care based on claims data received by Blue Cross from their providers.

How will I get paid?

Reference-based benefits won’t modify the current contract amount. Providers can expect to receive their contract rate on all procedures where reference-based benefits apply.

How will I know if a member is covered under reference-based benefits?

You can check the member’s benefits and eligibility on web-DENIS.

Do reference-based benefits apply to emergency services?

No. Reference-based benefits aren’t applicable to any service that is urgent or emergent.

How does the member identify services that are at or below the reference cost?

This information will be provided to members by their employer group. Members with reference-based benefits will be given access to consumer transparency tools to determine the cost of services.

What if members covered under reference-based benefits ask me for additional information about their benefits?

You can direct members to the transparency tools provided by their employer. Members who enroll in reference-based benefits will receive a welcome packet that gives them the tools they need to determine the cost of a particular episode of care.


Blue Cross to cover medical and pharmaceutical services for gender transition

Blue Cross Blue Shield of Michigan already provides gender transition benefits to many of its groups. Starting on Jan. 1, 2017, Blue Cross will extend these benefits to individuals and groups that currently have none or only some of them.

New benefits may include:

  • Gender reassignment surgery
  • Hormone therapy
  • Psychotherapy and counseling
  • Mastectomy for female to male transitions

Some surgical procedures will continue to require preauthorization. Always check a member’s eligibility and benefits.

Why are benefits for gender transition changing?

We’re changing our gender transition benefits in response to a final rule under Section 1557 of the Affordable Care Act. The rule, issued this year by the Department of Health and Human Services, prohibits discrimination on the basis of race, color, national origin, sex, age or disability in health programs or activities that receive federal financial assistance.

According to the rule, discrimination on the basis of sex includes discrimination based on gender identity. Protections for those seeking gender transition services are outlined in the rule.

This is the first time gender transition benefits have been mandated for health care coverage. This rule requires that gender transition benefits be available in health care plans starting on and after Jan. 1, 2017.

How will Blue Cross meet the requirements of the federal rule?

Blue Cross has been working to ensure its members will have access to these services no later than the start of their plan years, beginning on or after Jan. 1, 2017. Blue Cross groups and individuals will receive their enhanced benefits on Jan. 1, 2017, with the exception of NASCO Classic groups, which will receive them at the start of their 2017 plan year.


We’re streamlining EFT process

As of 9 p.m. Dec. 1, 2016, Blue Cross Blue Shield of Michigan will no longer require the use of an internal provider identification number, or PIN, when registering for electronic funds transfer, updating existing EFT bank information or canceling an EFT payment. Health care providers will be able to use their National Provider Identifier, or NPI, and the corresponding tax identification number instead.

Once a provider enters the NPI and tax ID number to register or make a necessary change, Blue Cross will systematically update all internal PINs and banking information affiliated with the NPI and tax ID.

Look for additional information about the updated EFT process in future web-DENIS messages and the December Record.


Here’s our policy on ‘DAW’ or ‘dispense as written’

BCN prescription drug programs
Blue Care Network will only cover the cost of a brand-name drug when the patient’s health care provider and BCN agree that the brand-name drug is medically necessary and that the generic drug was tried unsuccessfully or was not tolerated by the member.

Members need approval to receive tier 2 coverage for a DAW 1 indicator prescription. If the member doesn’t have approval, the member pays the difference between the cost of the generic and brand-name drug, plus the member’s brand-name copayment amount.

For DAW 2 indicator prescriptions, the member pays the difference between the cost of the generic and brand-name drug, plus the member’s brand-name copayment amount. BCN will reject all other DAW indicators, except DAW-5.

Blue Cross Blue Shield of Michigan follows the Michigan Public Health Code, which states that the prescribing health care provider must enter the initials “DAW” or the words “dispense as written” on the prescription in his or her own handwriting.

Our policy doesn’t allow payment for a multisource brand-name drug when the DAW indicator is preprinted or stamped, circled or checked off. DAW must also be appropriately noted on a phone order and initialed by the receiving pharmacist.

Each prescription stands on its own merit. This means that DAW indications on previous prescriptions don’t permit the dispensing of a brand-name drug when DAW isn’t present on another prescription for the same drug.

Member requesting a brand-name drug
If the member requests a brand-name drug, you must report a DAW 2 and inform the member that he or she will be responsible for the difference between the generic and the brand-name drug, plus any applicable copay amount. This is also true when the member requests a brand-name drug on the Maximum Allowable Cost program drug list and DAW is not indicated by the prescriber.

Audit
As stated above, preprinted DAW indicators aren’t acceptable. The pharmacists who dispense brand-name drugs for prescriptions with preprinted DAW indicators are entitled to the price of the generic drug only. When this error is found during an onsite audit, the pharmacy will incur a monetary sanction that amounts to the difference between the cost of the brand-name drug and the generic. This will be extrapolated. Auditors also routinely contact prescribing physicians to verify the authenticity of DAWs on prescriptions.

Electronically transmitted prescriptions
An electronic prescription allows the prescriber to instruct the pharmacist to dispense a brand-name drug product provided that the prescription includes both of the following:

  • The indication that no substitute is allowed, such as “dispense as written” or “DAW”
  • The indication that no substitute is allowed and that it is a unique element in the prescription

For more information
DAW may only be requested by the prescriber, not by the member, to justify reporting a dispensing indicator of “1.” If a member requests a brand-name drug when a generic alternative is available, a dispensing indicator of “2” should be reported.

You can find more information about DAW and the Maximum Allowable Cost program in the BCBSM/BCN Guide for Pharmacists.

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding, documentation and prescriptions are done in accordance with applicable state and federal laws and regulations.


2017 early-release CPT codes issued

The American Medical Association has issued a series of early-release Current Procedural Terminology codes for 2017 as follows. Only one code listed below is a Blue Cross Blue Shield of Michigan-covered benefit.

Surgery

Code*

Change

Coverage comments

Effective date

0446T

Added

Not covered

Jan. 1, 2017

0447T

Added

Not covered

Jan. 1, 2017

0448T

Added

Not covered

Jan. 1, 2017

0449T

Added

Not covered

Jan. 1, 2017

0450T

Added

Not covered

Jan. 1, 2017

0451T

Added

Not covered

Jan. 1, 2017

0452T

Added

Not covered

Jan. 1, 2017

0453T

Added

Not covered

Jan. 1, 2017

0454T

Added

Not covered

Jan. 1, 2017

0455T

Added

Not covered

Jan. 1, 2017

0456T

Added

Not covered

Jan. 1, 2017

0457T

Added

Not covered

Jan. 1, 2017

0458T

Added

Not covered

Jan. 1, 2017

0459T

Added

Not covered

Jan. 1, 2017

0460T

Added

Not covered

Jan. 1, 2017

0461T

Added

Not covered

Jan. 1, 2017

0462T

Added

Not covered

Jan. 1, 2017

0463T

Added

Not covered

Jan. 1, 2017

0465T

Added

Not covered

Jan. 1, 2017

0466T

Added

Not covered

Jan. 1, 2017

0467T

Added

Not covered

Jan. 1, 2017

0468T

Added

Not covered

Jan. 1, 2017

0466T

Added

Not covered

Jan. 1, 2017

Medicine

Code*

Change

Coverage comments

Effective date

0464T

Added

Not covered

Jan. 1, 2017

Medicine
Vaccines/Toxoids

Code*

Change

Coverage comments

Effective date

90674

Added

Covered

Jan. 1, 2017

90682

Added

Not covered

Jan. 1, 2017

90750

Added

Not covered

Jan. 1, 2017


Blue Cross to update McKesson ClaimsXten™ in January 2017

Blue Cross Blue Shield of Michigan will perform its quarterly ClaimsXten update in January 2017 to ensure that you have the most up-to-date codes to use on your claims.

ClaimsXten is clinical editing software that provides the most current Health Care Procedure Coding System codes, including Current Procedural Terminology codes. Using the most current procedure codes on your claims is important as it helps us process your claims and send accurate reimbursements quickly and efficiently.

Blue Cross works to ensure that ClaimsXten is aligned with all of our payment policies. We reserve the right to make changes or corrections as required or new information becomes available. In some instances, changes to ClaimsXten may be applied retroactively.

Note: Be sure to check out the January Record for information on new, revised or deleted procedure codes for 2017. We’ll include an article that will tell you how to find the “2017 HCPCS Update” on web-DENIS.


‘Provider consent to change’ option no longer available when calling Provider Inquiry

With the automation of both professional and facility replacement and void/cancel claims, we have removed the “provider consent to change” option from Provider Inquiry. If you have changes to a previously reported claim, report them on a claim form using the appropriate frequency codes: 7 for a replacement claim; 8 to void or cancel a claim.

Refer to the October Record for additional information on the appropriate reporting of replacement and void/cancel claims.

Provider Inquiry will continue to help you initiate an adjustment if you reported a valid and accurate claim but the claim did not process as expected. Examples include:

  • Facility dual diagnosis claims (screening versus diagnostic) when only the screening or diagnostic service was processed
  • Claims affected by a Blue Cross Blue Shield of Michigan system or processing issue

You may continue to receive calls from Customer Service on dual diagnosis facility claims or on a professional claim when we require additional information from you. We’re committed to resolving claim inquiries received from both providers and members on the first call if possible. If you can provide the information requested during the call — and a claim adjustment is appropriate — we’ll initiate it immediately on your behalf.

For more information on claim reporting, including links and articles to claim examples, reference the Claims chapter of the online provider manuals.


PARS to provide information on members’ remaining visits and days

Starting in December 2016, the Provider Automated Response System, or PARS, will be enhanced to provide members’ remaining number of visits and days in the benefit period for chiropractic services, cardiac rehabilitation services and physical therapy.

This enhancement will allow health care providers to obtain even more information about their patients by using the system. We’ll provide additional details in future communications.


Coding corner reminder: Best practices for documenting diabetes

With the implementation of ICD-10-CM and coding classification changes, there are now combination codes for diabetes and its associated conditions and manifestations. Specificity of documentation is more important than ever.

Providers either report Type 1 diabetes for patients who don’t produce insulin or Type 2 diabetes for patients who produce insulin but their bodies don’t use it correctly.

To improve documentation and coding practices, it’s essential that medical records provide details on all diabetes-related conditions to the highest level of specificity known.

When documenting diabetes, consider the following:

  • Specify whether it’s Type 1 or Type 2 diabetes. When the type isn’t documented in the medical record, the default code would be for Type 2 diabetes mellitus.
  • Is the diabetes due to a condition or a drug? If it’s due to a drug, indicate which one.
  • Is this a secondary type of diabetes? If so, what’s the cause?
  • Specify when diabetes is gestational.
  • Was there an incidence of underdosing or overdosing (poisoning)? For example: Did the patient receive too much or not enough insulin?
  • Document current status on the diabetes and all associated conditions.

How to improve progress notes
Only providers can diagnose a patient’s medical condition, making documentation even more important. Even if a medical coder can recognize the inference of a condition, only what is documented can be coded.

Example: Type 2 diabetes mellitus with macular edema

  1. It is necessary to also document retinopathy; “Diabetes, retinopathy, with macular edema” - E11.311

For instance, if a patient has two medical conditions that are linked, then his or her provider should document that the conditions are related. This allows coders to use a combination code, which is a single code used to describe two diagnoses (a diagnosis with either an associated manifestation or complication).

Example: Type 1 diabetic mellitus with severe nonproliferative diabetic retinopathy with macula edema

Here are three examples of when a report lacks documentation or doesn’t properly link two conditions:

  1. A patient visits his podiatrist for an annual diabetic exam. The podiatrist documents a prescription for new shoes. The assessment shows the patient is instructed to return in one year.

    What’s wrong with this documentation?
    • The medical coder can’t code the patient’s medical condition as diabetes because the provider didn’t document the patient as being diabetic.
    • The annual diabetic exam may have only been for monitoring purposes; it doesn’t prove the patient has the condition.
  2. A patient visits his podiatrist for an annual diabetes exam. The podiatrist documents a prescription for new shoes. The assessment shows the patient understands the importance of checking his feet, because his diabetic condition makes his feet prone to other health issues.

    What’s wrong with this documentation?
    • The provider’s note only states the patient is diabetic.
    • The documentation should state any linked or additional diagnoses. Peripheral neuropathy maybe suspected based on the prescription for diabetic shoes, but the provider didn’t document that condition.
  3. A patient visits his podiatrist for an annual diabetes exam. The podiatrist documents a prescription for new shoes. The assessment shows peripheral neuropathy and that the patient understands the importance of checking his feet, because his diabetic condition makes his feet prone to other health issues.

    What’s wrong with this documentation?
    • The documentation doesn’t support a relationship between the two conditions. Therefore, they would be coded as two separate diagnoses instead of diabetes with a manifestation or complication.
    • To link two medical conditions together, there needs to be verbiage in the record such as “with,” “due to” or “associated with.”

It’s equally important for everyone involved in the patient’s care to understand the relationship of the conditions found in the progress notes. Documenting the cause and effect of a condition in the medical record provides a complete picture of the patient’s office visit.

It’s the health care provider’s responsibility to document when diabetes mellitus is not the underlying cause of other conditions. The fact that a patient has two or more conditions that commonly occur together doesn’t necessarily mean they are related.

The ICD-10 code assignment is crucial in determining the correct reimbursement for these face-to-face encounters and for tracking health care services provided for a diabetic condition.

Requirements for reporting diabetes mellitus and its associated illnesses are located in the ICD-10-CM coding book, “Chapter 4: Endocrine, Nutritional, and Metabolic Diseases (E00 – E89).”

References: Coding Clinic, First and Second Quarter Issues, 2016

None of the information included in this article is intended to be legal advice and, as such, it remains the provider’s responsibility to ensure that all coding and documentation are done in accordance with applicable state and federal laws and regulations.


BlueCard® connection: Why was my claim for a Medicaid-enrolled member rejected?

Claims for Medicaid-enrolled members must be billed according to Medicaid reporting requirements. When a member is enrolled in a Medicaid plan in another state — and the Medicaid plan is administered by a Blue plan — your claim will be routed to the plan where the member is enrolled. The member’s three-letter alpha-prefix identifies the plan and state where the patient is enrolled.

Plans may also require you to register as a Medicaid provider with their plans before approving reimbursement on the claim. To ensure you’re billing the claim accurately and have met the plan’s state Medicaid requirements, be sure to verify your patient’s eligibility and benefits. Failure to report the claim according to Medicaid requirements could result in a request from the plan for additional information or a claim denial.

For more information on the BlueCard program, including links and articles on online tools, reference the BlueCard chapter of the online provider manuals.

Have a question you’d like answered?
If you’re experiencing issues with the information provided in the BlueCard chapter of the online manual — or if you’d like more information on a particular topic — contact your provider consultant.

Want to suggest a topic to be covered in this series? Send an email to ProvComm@bcbsm.com and put “BlueCard series” in the subject line.


Billing chart: Blues highlight medical, benefit policy changes

You’ll find the latest information about procedure codes and Blue Cross Blue Shield of Michigan billing guidelines in the following chart.

This billing chart is organized numerically by procedure code. Newly approved procedures will appear under the New Payable Procedures heading. Procedures for which we have changed a billing guideline or added a new payable group will appear under Updates to Payable Procedures. Procedures for which we are clarifying our guidelines will appear under Policy Clarifications. New procedures that are not covered will appear under Experimental Procedures.

You will also see that descriptions for the codes are no longer included. This is a result of recent negotiations with the AMA on use of the codes.

We will publish information about new BCBS groups or changes to group benefits under the Group Benefit Changes heading.

For more detailed descriptions of the BCBSM policies for these procedures, please check under the Medical/Payment Policy tab in Explainer on web-DENIS. To access this online information:

  • Log in to web-DENIS.
  • Click on BCBSM Provider Publications & Resources.
  • Click on Benefit Policy for a Code.
  • Click on Topic.
  • Under Topic Criteria, click on the drop-down arrow next to Choose Identifier Type and then click on HCPCS Code.
  • Enter the procedure code.
  • Click on Finish.
  • Click on Search.
Code* BCBSM changes to:
Basic Benefit and Medical Policy, Group
Variations Payment Policy, Guidelines
NEW PAYABLE PROCEDURES

A4555, E0766

Experimental: A9900, E1399, 77299

Basic benefit and medical policy

TTF therapy for the treatment of supratentorial glioblastoma

The safety and effectiveness of tumor-treatment fields, or TTF, therapy has been established for the treatment of supratentorial glioblastoma. TTF therapy may be medically necessary when used under the care of a doctor, in adults 22 and older and as an adjunct therapy to standard therapy; for a newly histologically confirmed supratentorial glioblastoma or upon reoccurrence as an alternative to chemotherapy.

This policy was effective May 1, 2016.

Inclusions:
Tumor treatment field therapy may be medically necessary, under the care of a doctor, in the treatment of glioblastoma multiforme in all of the following:

  • Adults (22 and older)
  • Newly diagnosed histologically confirmed supratentorial glioblastomas:
    • In adults (22 and older) and
    • When used as an adjunct therapy to standard treatments that include maximal debulking surgery and completion of radiation together with the chemotherapy drug temozolomide, or TMZ, or
    • Reoccurrence of histologically or radiologically confirmed supratentorial glioblastoma
    • The device may be used as a monotherapy or as an alternative to standard medical therapy

Exclusions:
Tumor treatment field therapy is considered experimental when:

  • Combined with chemotherapy other than TMZ
  • Used for any indications other than those listed above
UPDATES TO PAYABLE PROCEDURES

20974, 20975, E0747

Basic benefit and medical policy

Use of monitored anesthesia care

The monitored anesthesia care for endoscopic, surgical and other diagnostic and therapeutic procedures policy is established. This policy was effective Sept. 1, 2016.

Medical policy statement
Use of monitored anesthesia care may be considered established for gastrointestinal endoscopy procedures when there is documentation by the proceduralist or anesthesiologist that specific risk factors or significant medical conditions are present supporting the opinion that the procedure can’t be done successfully or safely in the absence of monitored anesthesia care.

Inclusions:

Monitored anesthesia care is considered medically necessary for patients with risk factors or significant medical conditions that increase the risk of sedation, including any of the following:

  • Increased risk for complications due to severe comorbidity (ASA P3* or greater)
  • Morbid obesity (body mass index greater than 40)
  • Documented sleep apnea
  • Inability to follow simple commands (cognitive dysfunction, intoxication, or psychological impairment)
  • Spasticity or movement disorder complicating procedure
  • History or anticipated intolerance to standard sedatives, such as:
    • Chronic opioid use
    • Chronic benzodiazepine use
  • Patients with active medical problems related to drug or alcohol abuse
  • Patients younger than age 12 or age 70 or older
  • Patients who are pregnant
  • Patients with increased risk for airway obstruction due to anatomic variation, such as:
    • History of stridor
    • Dysmorphic facial features
    • Oral abnormalities (e.g., macroglossia)
    • Neck abnormalities (e.g., neck mass)
    • Jaw abnormalities (e.g., micrognathia)
  • Acutely agitated, uncooperative patients
  • Prolonged or therapeutic gastrointestinal endoscopy procedures requiring deep sedation (e.g., endoscopic retrograde cholangiopancreatography, transduodenal biopsy, double balloon enteroscopy).

Exclusions:

Monitored anesthesia care is considered not medically necessary for gastrointestinal endoscopic, bronchoscopic or interventional pain procedures in patients at average risk for anesthesia and sedation.

S2095, 37243, 79445

Basic benefit and medical policy

Radioembolization for primary and metastatic tumors of the liver 
The safety and effectiveness of radioembolization for primary and metastatic tumors of the liver have been established. It may be considered a useful therapeutic option when indicated. This policy is effective Nov. 1, 2016.

Inclusions:

  • Primary hepatocellular carcinoma that is unresectable and limited to the liver
  • Primary hepatocellular carcinoma as a bridge to liver transplantation
  • Hepatic metastases from neuroendocrine tumors (carcinoid and noncarcinoid) with diffuse and symptomatic disease when systemic therapy has failed to control symptoms
  • Unresectable hepatic metastases from colorectal carcinoma, melanoma (ocular or cutaneous) or breast cancer that are both progressive and diffuse, in patients with liver-dominant disease who are refractory to chemotherapy or aren’t candidates for chemotherapy or other systemic therapies
  • Primary intrahepatic cholangiocarcinoma in patients with unresectable tumors
  • Treatment of other radiosensitive tumors metastatic to the liver with liver-limited or liver-dominant disease for symptom palliation or prolongation of survival

One of the following criteria must be met for unresectable hepatocellular carcinoma:

  • Multiple liver metastases together with involvement of both lobes
  • Tumor invasion where the three hepatic veins enter the inferior vena cava
  • None of the hepatic veins could be preserved if the metastases were resected
  • Tumor invasion of the porta hepatis such that neither the origin of the right nor left portal veins could be preserved if resection were undertaken
  • Widespread metastases such that resection would leave less liver than is compatible with survival

Exclusions:

  • Used to treat, previously untreated, unresectable, hepatic metastases from colorectal carcinoma
  • For all other hepatic metastases not described above
  • For all other indications not described above

Yttrium-90 is contraindicated for patients who have:

  • Had previous external beam radiation therapy of the liver
  • Bleeding diathesis not correctable using standard medical means
  • Severe pulmonary insufficiency
  • Treatment that would result in greater than 30 Gy dose to the lung in one session or 50 Gy cumulative as assessed by Technetium MAA scan
  • Pre-assessment angiogram that demonstrates vascular anatomy abnormalities that would result in significant reflux of hepatic arterial blood to the stomach, pancreas or bowel
  • Disseminated and significant extrahepatic malignant disease
  • History of treatment with capecitabine within two previous months, or who will be treated with capecitabine at any time following treatment with SIR-Spheres®
  • Portal vein thrombosis (relative)

Yytrium-90 has relative contraindications for patients who have:

  • Ascites or are in clinical liver failure
  • Markedly abnormal liver function tests

Radioembolization isn’t recommended in pregnant women, nursing mothers or children.

J9310

Basic benefit and medical policy

Dexamethasone to treat patients with neuromyelitis optica

Blue Cross Blue Shield of Michigan has approved dexamethasone for off-label use to treat patients with neuromyelitis optica, also known as Devic's disease, when reported with procedure code J9310 and ICD 10 diagnosis G36.0.

The doctor who prescribes this drug for off-label use must determine the appropriate dose when used other than that approved by the FDA.

POLICY CLARIFICATIONS

*Various, 81479

Basic benefit and medical policy

Genetic testing for carrier status of genetic diseases

The criteria for the genetic testing for carrier status of genetic diseases policy have been clarified. This policy is effective Nov. 1, 2016.

Inclusions:
Carrier testing for genetic diseases is established when one of the following criteria is met:

  • One or both individuals have a first- or second-degree relative who is affected
  • First degree includes biological: parent, sibling and child
  • Second degree includes biological: grandparent, aunt, uncle, niece, nephew, grandchildren and half-sibling
  • One individual is known to be a carrier
  • One or both individuals are members of a population known to have a carrier rate that exceeds a threshold considered appropriate for testing for a particular condition

And all of the following criteria are met:

  • The natural history of the disease is well understood and there is a reasonable likelihood that the disease is one with high morbidity in the homozygous or compound heterozygous state.
  • Alternative biochemical or other clinical tests to definitively diagnose carrier status are not available, or, if available, provide an indeterminate result or are individually less efficacious than genetic testing.
  • The genetic test has adequate sensitivity and specificity to guide clinical decision-making and residual risk is understood.
  • An association of the marker with the disorder has been established.

Exclusions:
Expanded carrier screening panels are generally considered experimental. There is insufficient evidence that such tests affect clinical outcomes incrementally greater than traditional genetic testing.

Expanded carrier testing is excluded except when each individual genetic mutation included in the panel meets criteria listed above under “inclusions” (e.g., panel for Ashkenazi Jewish ethnicity).

Reimbursement for expanded carrier testing may receive individual consideration depending on comparative fees and charges.

0249T

Basic benefit and medical policy

Transanal hemorrhoidal dearterialization is experimental

Transanal hemorrhoidal dearterialization is experimental. This procedure has not been shown to improve long-term clinical outcomes better than conventional surgical treatment for hemorrhoids. The policy has been reviewed and updated, effective Nov. 1, 2016.

99183, G0277

Experimental: A4575, E0446

Basic benefit and medical policy

Systemic hyperbaric oxygen therapy Headline

The safety and effectiveness of systemic hyperbaric oxygen therapy have been established for some conditions. It may be considered a useful therapeutic option when indicated for specified conditions.

Topical hyperbaric oxygen therapy is experimental. It hasn’t been scientifically demonstrated to improve patient clinical outcomes. The criteria have been updated, effective Nov. 1, 2016.

Inclusions:
Note: Some locations may be excluded, check with carrier for location restrictions.

The following conditions are effectively treated by systemic hyperbaric oxygen therapy (this list may not be all-inclusive):

  • Actinomycosis, only as an adjunct to conventional therapy when the disease process is refractory to antibiotics and surgical treatment
  • Acute carbon monoxide intoxication
  • Acute peripheral arterial insufficiency
  • Acute traumatic peripheral ischemia: HBOT is a valuable adjunctive treatment to be used in combination with accepted standard therapeutic measures when loss of function, limb or life is threatened
  • Carbon monoxide poisoning, acute
  • Chronic refractory osteomyelitis, unresponsive to conventional medical and surgical management
  • Crush injuries and suturing of severed limbs as an adjunctive treatment when loss of function, limb or life is threatened
  • Cyanide poisoning, acute
  • Decompression illness
  • Gas embolism, acute
  • Gas gangrene (i.e., clostridial myonecrosis)
  • Osteoradionecrosis and soft tissue radiation necrosis as an adjunct to conventional treatment
  • Pre- and post-treatment for patients undergoing dental surgery (non-implant related) of an irradiated jaw
  • Preparation and preservation of compromised skin grafts (not for primary management of wounds)
  • Profound anemia with exceptional blood loss: only when blood transfusion is impossible or must be delayed
  • Progressive necrotizing infections
  • Refractory mycoses: mucormycosis, actinomycosis, Conidiobolus coronata only as an adjunct to conventional therapy when the disease process is refractory to antibiotics and surgical treatment

Treatment of wounds using hyperbaric oxygen therapy may be appropriate when there have been no measurable signs of healing for at least 30 consecutive days or when there is failure to respond to standard wound care. Wounds must be evaluated at least every 30 days during administration of HBOT for measurable signs of improvement. Continued treatment with HBOT should be discontinued when there are no measurable signs of healing within any 30-day period of treatment.

Wounds, including diabetic wounds, being treated with hyperbaric oxygen therapy must be reviewed using clinical documentation that identifies measurable signs of healing, e.g., width, depth and length of the wound.

Additional criteria for diabetic wounds:
Diabetic wounds of the lower extremities in patients who meet the following three criteria:

  • A diagnosis of type 1 or type 2 diabetes with a lower extremity wound that is due to diabetes
  • A wound classified as Wagner grade III or higher. (The Wagner classification system of wounds is defined as follows: grade 0 = no open lesion; grade 1 = superficial ulcer without penetration to deeper layers; grade 2 = ulcer penetrates to tendon, bone, or joint; grade 3 = lesion has penetrated deeper than grade 2 and there is abscess, osteomyelitis, pyarthrosis, plantar space abscess, or infection of the tendon and tendon sheaths; grade 4 = wet or dry gangrene in the toes or forefoot; grade 5 = gangrene involves the whole foot or such a percentage that no local procedures are possible and amputation [at least at the below the knee level] is indicated.)
  • The patient has failed an adequate course of standard wound therapy. Standard wound care in patients with diabetic wounds includes all of the following:
    • The assessment of a patient’s vascular status and correction of any vascular problems in the affected limb if possible
    • The optimization of nutritional status
    • Optimization of glucose control
    • Debridement by any means to remove devitalized tissue
    • Maintenance of a clean, moist bed of granulation tissue with appropriate moist dressings
    • Appropriate off-loading
    • Necessary treatment to resolve any infection that might be present

For several of the indications included, there is little published evidence to support the effectiveness of hyperbaric oxygen therapy. However, there is little likelihood of RCTs being done for such relatively rare indications. Generally, these patients present with clinically severe situations where therapeutic options are limited. Subject matter expert experience and limited available evidence support that hyperbaric oxygen treatment may offer therapeutic benefit in these cases.

Exclusions:
Hyperbaric oxygen pressurization is considered investigational in the treatment of the following conditions (this list may not be all-inclusive):

  • Acute coronary syndromes and as an adjunct to coronary interventions, including percutaneous coronary interventions and cardiopulmonary bypass
  • Acute or chronic cerebral vascular insufficiency
  • Acute ischemic stroke
  • Acute thermal and chemical pulmonary damage, i.e., smoke inhalation with pulmonary insufficiency
  • Acute thermal burns
  • Acute surgical and traumatic wounds
  • Aerobic septicemia
  • Anaerobic septicemia and infection other than clostridial
  • Arthritic diseases
  • Autism spectrum disorders
  • Bell palsy
  • Bisphosphonate-related osteonecrosis of the jaw
  • Bone grafts
  • Brown recluse spider bites
  • Carbon tetrachloride poisoning, acute
  • Cardiogenic shock
  • Cerebral edema, acute
  • Cerebral palsy
  • Cerebrovascular disease, acute (thrombotic or embolic) or chronic
  • Chronic arm lymphedema following radiotherapy for cancer
  • Chronic peripheral vascular insufficiency
  • Chronic aerobic refractory osteomyelitis and acute osteomyelitis, refractory to standard medical management
  • Chronic wounds, other than those situations under the inclusions
  • Cosmetic use
  • Cutaneous, decubitus and stasis ulcers
  • Delayed onset muscle soreness
  • Demyelinating diseases, e.g., multiple sclerosis, amyotrophic lateral sclerosis
  • Early treatment (beginning at completion of radiation therapy) to reduce side effects of radiation therapy
  • Exceptional blood loss anemia
  • Fibromyalgia
  • Fracture healing
  • Hepatic necrosis
  • Herpes zoster
  • Hydrogen sulfide poisoning
  • Idiopathic femoral neck necrosis
  • Idiopathic sudden sensorineural hearing loss
  • Inflammatory bowel disease (Crohn’s disease or ulcerative colitis)
  • Intra-abdominal and intracranial abscesses
  • In vitro fertilization
  • Lepromatous leprosy
  • Meningitis
  • Mental illness (i.e., posttraumatic stress disorder, generalized anxiety disorder or depression)
  • Migraine
  • Motor dysfunction associated with stroke
  • Multiple sclerosis
  • Myocardial infarction
  • Nonvascular causes of chronic brain syndrome (Pick’s disease, Alzheimer’s disease, Korsakoff’s disease)
  • Organ storage
  • Organ transplantation
  • Pseudomembranous colitis (antimicrobial agent-induced colitis)
  • Pulmonary emphysema
  • Pyoderma gangrenosum
  • Radiation myelitis, cystitis, enteritis or proctitis
  • Radiation-induced injury in the head and neck, except as noted under the inclusions
  • Refractory mycoses; mucormycosis, actinomycosis, conidiobolus coronato
  • Retinal artery insufficiency, acute
  • Retinopathy, adjunct to scleral buckling procedures in patients with sickle cell peripheral retinopathy and retinal detachment
  • Senility
  • Severe or refractory Crohn’s disease
  • Sickle cell crisis and hematuria
  • Skin burns (thermal)
  • Spinal cord injury
  • Systemic aerobic infection
  • Tetanus
  • Traumatic brain injury
  • Tumor sensitization for cancer treatments, including radiotherapy or chemotherapy
  • Vascular dementia
POLICY CLARIFICATIONS

93050

Basic benefit and medical policy

SphygmoCor® System for noninvasive measurement of central blood pressure

SphygmoCor® System for noninvasive measurement of central blood pressure isn’t an established or medically necessary procedure. While SphygmoCor System for noninvasive measurement of central blood pressure may be safe, its effectiveness in this clinical indication has not been scientifically determined. Therefore, this service is experimental, effective Nov. 1, 2016.

83006

Basic benefit and medical policy

Presage ST2 Assay

The use of the Presage ST2 Assay is considered experimental for the following:

  • Evaluating the prognosis of patients diagnosed with chronic heart failure
  • Guide management (e.g., pharmacological, device-based, exercise) of patients diagnosed with chronic heart failure OR
  • In the post cardiac transplantation period, including, but not limited to, predicting prognosis and predicting acute cellular rejection

The policy has been updated, effective Nov. 1, 2016.


Professionals

Commercial prescription drug plans will have out-of-pocket maximum when paired with Medicare supplement products

Effective Jan. 1, 2017, group members with commercial prescription drug plans will have a $7,150 out-of-pocket maximum applied to their plans when they’re paired with Blue Cross Blue Shield of Michigan Medicare supplement products or BCN 65. Members who reach their out-of-pocket maximum will have their prescription drugs covered in full for the rest of their plan year.

The new out-of-pocket maximum applies only to prescription coverage. The change doesn’t apply to grandfathered or retiree-only groups.

Keep the following in mind:

  • A Blue Cross Medicare supplement plan is a commercial PPO product that is secondary to Medicare. It can be paired with a commercial prescription drug plan.
  • BCN 65 is a commercial HMO product that is secondary to Medicare. BCN 65 covers Medicare copayments, coinsurance and deductibles, and provides some additional benefits such as preventive care.

Certain high-cost products to treat skin conditions won’t be covered due to comparable alternatives

As you read in the September Record, Blue Cross Blue Shield of Michigan commercial plans don’t cover select high-cost, FDA-approved drugs for which more cost-effective therapeutic alternatives are available. This is part of an ongoing effort to address the high cost of drugs and provide the best possible value for our members.

Ultravate®-X kits, Ultravate® lotion, Cordran® lotion, flurandrenolide lotion and Locoid® lotion, which are topical products used to treat corticosteroid-responsive skin conditions, have been targeted for exclusion, effective Oct. 7, 2016. Members currently using these drugs can continue to fill prescriptions for them through Dec. 31, 2016.

The following table includes the approximate cost of the targeted drugs and the associated therapeutic alternatives:

Drug names not covered and their costs**

Covered therapeutic alternatives and their costs**

Locoid® lotion (hydrocortisone butyrate)

$1,046

Cordran® lotion (flurandrenolide)

$1,101

flurandrenolide lotion

$990

betamethasone dipropionate lotion (Diprosone®)

$47

betamethasone valerate lotion (Valisone®)

$72

triamcinolone lotion (Aristocort, Kenalog®)

$90

Ultravate® lotion (halobetasol propionate)

$1,083

Ultravate®-X cream kit
(halobetasol + lac-hydrin, OTC)

$1,083

Ultravate®-X ointment kit
(halobetasol + lac-hydrin, OTC)

$1,083

augmented betamethasone
dipropionate- cream, ointment, lotion (Diprolene®)

$75 - $186

clobetasol propionate- cream, ointment (Temovate®)

$459 - $520

fluocinonide- cream, ointment (Lidex®,
Lidex-E®)

$182 - $293

halobetasol propionate- cream,
ointment (Ultravate®)

$191

**Approximate cost for a 30-day supply based on the average wholesale price.

In some cases, members’ out-of-pocket costs for these brand-name drugs may be lower than their copay due to manufacturer savings cards. However, the high cost of these drugs will be reflected in future premium rates and the overall claims experience for members and plans.

As part of this ongoing initiative, Blue Cross will continue to identify select high-cost drugs and will stop covering them when there are more cost-effective alternatives available for our commercial members.


Assess, compare your chiropractic clinical performance with Optum™ WebAssist

Helpful hint

Regular use of the Optum WebAssist provider portal allows you to assess and continually improve your clinical performance.

Blue Cross Blue Shield of Michigan is committed to transparency when it comes to sharing performance data and helping clinicians provide care that is well-aligned with current, evidence-based best practices.

That’s why we’re working with our chiropractic partner, Optum, to help you maximize the valuable resources found on the secure Optum® WebAssist provider portal.** The vast library of resources available to you 24 hours a day, seven days a week features a personalized clinical profile that compares your performance against same-specialty peers within the Blue Cross network.

This article includes answers to two questions we hear frequently from our participating chiropractors:

  • What information is available to me in my profile?
  • What’s the best way to review the data?

Here’s what you need to know about the WebAssist provider portal:

  • It allows for a review of the current year and the previous three calendar years.
  • Data can be reviewed by quarter, year or at six-month intervals.
  • Data is updated monthly; with the date of refresh indicated on the site.
  • Data is aggregated by health plan.
  • It offers comparisons to same-specialty peers treating patients from the same health plan during the same time frame.
  • It features “run charts” and “bubble charts” for most key performance indicators.
    • Run charts contain the mean and standard deviation for high-volume peers treating patients from the same health plan, as well as the specific provider trend.
    • Bubble charts allow a provider to view their performance against a specific metric in comparison to other network providers.
  • It includes literature and guidelines related to key performance indicators.
  • It allows you to review various reports regarding treatment, coding, therapy use and demographics. The summary and treatment reports will give you a general overview of multiple clinical parameters.

Tips for using WebAssist

  • Viewing quarterly interval data from your profile is useful for seeing the most recent changes you’ve made in your practice.
  • If you want to see how your clinical performance is progressing for the calendar year, check out the annual time interval.
  • You can’t focus solely on the quarterly results and then add each quarter up — or use them independently — to determine your annual performance because you may be treating the same patient in multiple quarters.
  • Only the annual report will display your performance for patients treated across the entire calendar year to date.

You’ll need your Optum provider ID and password to access your data on the Optum provider portal. If you haven’t received your Optum provider ID or password — or if you you need this information resent to you — contact Optum at 1-800-873-4575.

If you have any questions or want to discuss your clinical profile, call 1-800-873-4575 and ask to speak with your assigned Optum support clinician. Or call them direct at 1-952-205-3121 or 1-952-202-3496.

**Blue Cross Blue Shield of Michigna does not own or control the content of this website.


We’ve made some changes to our allergy antigens policy

Our allergy antigens policy has been updated since we communicated about it in the March 2016 Record. Please refer to the information that follows for details on our allergy antigens policy.

When billing procedure code *95165 for allergy antigens preparations, health care providers are required to specify the number of anticipated doses to prepare as units.

A dose, or unit, won’t be defined as one cubic centimeter. It will be defined as the amount of serum injected into the patient at the time of treatment.

Procedure code *95165 should be billed on a separate line for each multi-dose vial prepared with the number of anticipated doses at the time of preparation.

Providers may bill for:

  • Preparation of a reasonable supply of allergy antigen at one time
  • No more than a 12-month supply
  • Unused prepared antigen left over after the patient begins treatment

Patients may ask that the antigen is mixed in preparation of immunotherapy. However, if the patient doesn’t begin the treatment, the patient is responsible for the cost of the preparation and provision of the antigen.

Patients should be notified of any potential liability at the time they request treatment. Providers should use the Advance Notice of Member Responsibility form to document that they have informed patients of this potential liability.

To sum up, Blue Cross shouldn’t be billed for an antigen that isn’t administered to the patient.


FluMist® not covered for 2016-17 flu season

Effective Oct. 1, 2016, Blue Cross Blue Shield of Michigan is not covering the FluMist nasal spray vaccine for the 2016-17 flu season. The corresponding procedure codes are *90660 and *90672.

This decision is based on a recommendation from the Centers for Disease Control and Prevention. Data has shown that the nasal spray is less effective than flu shots in protecting against the flu.

We encourage our members to get an annual flu vaccination.


Michigan BAC and MPSERS members to participate in Medical Drug Prior Authorization Program

Beginning Jan. 1, 2017, members of the Michigan Bricklayers and Allied Crafts Health Care Fund, or Michigan BAC, and the Michigan Public School Employees Retirement System, or MPSERS, will participate in the Medical Drug Prior Authorization Program.

This program does not apply to Medicare, Medicare Advantage or Federal Employee Program® members.

The chart below lists the medications that are part of the Medical Drug Prior Authorization Program.

Drug names

Actemra®

Depo®-Testosterone

Kalbitor®

Signifor® LAR

Acthar® gel

Dysport®

Kanuma™

Simponi Aria®

Adagen®

Elaprase®

Krystexxa®

Soliris®

Aldurazyme®

Elelyso™

Lemtrada™

Stelara®

Aralast NP™

Entyvio™

Lumizyme®

Stelara IV®

Aveed®

Fabrazyme®

Makena®

Synagis®

Benlysta®

Firazyr®

Myobloc®

Testopel®

Berinert®

Flebogamma® DIF

Myozyme®

Tysabri®

Bivigam™

Gammagard Liquid®

Naglazyme®

Vimizim™

Botox®

Gammagard® S/D

Nplate®

Vpriv®

Carimune® NF

Gammaked®

Nucala®

Xeomin®

Cerezyme®

Gammaplex®

Octagam®

Xgeva®

Cimzia®

Gamunex®

Orencia®

Xiaflex®

Cinqair®

Glassia™

Privigen®

Xolair®

Cinryze®

Hizentra®

Probuphine®

Zemaira®

Cosentyx™

HyQvia®

Prolastin®-C

Cuvitru®

Ilaris®

Prolia®

Delatestryl®

Immune globulin

Ruconest®


Vitamins B6, B12 shots should only be given when medically necessary

Vitamin B6 and vitamin B12 injections and infusions should only be billed when medically necessary for patients who have a documented deficiency.

Doctors must clearly document the reason for giving vitamin B6 and vitamin B12 injections and infusions in the patient’s medical record.

We will not pay for these procedures when given for weight reduction purposes.


We’ll monitor use of 2 frequently misused E&M codes

Blue Cross Blue Shield of Michigan will closely monitor the use of two evaluation and management procedure codes that are frequently misused — office visits *99214 and *99215.

A review of how these codes are used revealed they are often based on the stored patient history in electronic medical records rather than on the services that were actually rendered. This can result in a higher-level service being billed when a lower-level service is warranted, sometimes called upcoding.

To avoid clinical inquires about E&M services you provide, be sure to carefully document and code each service according to the national coding guidelines. The CMS Evaluation and Management Services Guide is a good resource for coding guidelines.


Coverage for procedure code *61630 ending in 2017

Starting Jan. 1, 2017, Blue Cross Blue Shield of Michigan will no longer provide coverage for procedure code *61630.

Refer to the medical policy for Endovascular Procedures for Intracranial Arterial Disease (Atherosclerosis and Aneurysms), dated Nov. 1, 2016, for a list of related procedures and services that may be covered.


Reminder: Procedure codes for transitional care management

As we wrote in the August 2015 Record, procedure code *99495 is not payable for Blue Cross Blue Shield of Michigan contracts, with the exception of Federal Employee Program® members, and procedure code *99496 is payable for all cases of transitional care management.

The provider must communicate directly with the patient or caregiver by phone, text, fax or email within two days of discharge from:

  • An inpatient hospital
  • A skilled nursing facility
  • A community mental health center
  • An outpatient observation
  • A partial hospitalization

A face-to-face visit must occur within seven business days of the patient’s discharge.

Services performed during the face-to-face visit must take place in conjunction with the appropriate non-face-to-face transitional care management services outlined within the Transitional Care Management Services section of the CPT manual.


Facility

Bill new corrected original when reporting a modifier change on outpatient psychiatric claim

A replacement claim (frequency code 7) cannot be reported when changing the modifier on an OPC claim.

The modifier or the absence of a modifier on a claim identifies the level of therapist rendering the service to your patient. This changes the provider’s demographics on the claim.

As we explained in a June 2016 Record article, any change to patient or provider demographics, NPI, provider PIN or taxonomy code requires that you void or cancel your original paid claim, and report the member or provider change in a new, corrected original.

To avoid canceling your original claim, be sure you report the correct modifier on the original CMS-1500 claim form. Use field 24D-PROCEDURES OR SUPPLIES to identify the level of therapist who provided the service. Correct therapist-level codes are:

Code

Level

AH

Fully-licensed psychologist

AJ

  • Licensed master’s level social worker
  • Clinical social worker

HO

Master’s-level clinician:

  • Certified nurse practitioner
  • Licensed professional counselor
  • Limited licensed psychologist
  • Licensed marriage and family therapist

 

Note: For board-certified or board eligible psychiatrists, leave the code area blank.

On the CMS-1500 claim form, in field 24J - RENDERING PROVIDER ID, leave both the shaded and unshaded areas blank.

A replacement claim (frequency code 7) should be reported when changing a procedure code, charge or quantity on the claim.

Want to learn more?

For more information on outpatient psychiatric care claims, including helpful articles, examples and links, go to the Claims chapter of the OPC online provider manual.


2016 HCPCS maintenance

The Centers for Medicare & Medicaid Services recently released the following 2016 HCPCS code, retroactive to Jan. 1, 2016:

Chemo Admin

Code

Change

Coverage comments

Effective date

G0498

Added

Covered

Jan. 1, 2016


Pharmacy

Certain high-cost products to treat skin conditions won’t be covered due to comparable alternatives

As you read in the September Record, Blue Cross Blue Shield of Michigan commercial plans don’t cover select high-cost, FDA-approved drugs for which more cost-effective therapeutic alternatives are available. This is part of an ongoing effort to address the high cost of drugs and provide the best possible value for our members.

Ultravate®-X kits, Ultravate® lotion, Cordran® lotion, flurandrenolide lotion and Locoid® lotion, which are topical products used to treat corticosteroid-responsive skin conditions, have been targeted for exclusion, effective Oct. 7, 2016. Members currently using these drugs can continue to fill prescriptions for them through Dec. 31, 2016.

The following table includes the approximate cost of the targeted drugs and the associated therapeutic alternatives:

Drug names not covered and their costs**

Covered therapeutic alternatives and their costs**

Locoid® lotion (hydrocortisone butyrate)

$1,046

Cordran® lotion (flurandrenolide)

$1,101

flurandrenolide lotion

$990

betamethasone dipropionate lotion (Diprosone®)

$47

betamethasone valerate lotion (Valisone®)

$72

triamcinolone lotion (Aristocort, Kenalog®)

$90

Ultravate® lotion (halobetasol propionate)

$1,083

Ultravate®-X cream kit
(halobetasol + lac-hydrin, OTC)

$1,083

Ultravate®-X ointment kit
(halobetasol + lac-hydrin, OTC)

$1,083

augmented betamethasone
dipropionate- cream, ointment, lotion (Diprolene®)

$75 - $186

clobetasol propionate- cream, ointment (Temovate®)

$459 - $520

fluocinonide- cream, ointment (Lidex®,
Lidex-E®)

$182 - $293

halobetasol propionate- cream,
ointment (Ultravate®)

$191

**Approximate cost for a 30-day supply based on the average wholesale price.

In some cases, members’ out-of-pocket costs for these brand-name drugs may be lower than their copay due to manufacturer savings cards. However, the high cost of these drugs will be reflected in future premium rates and the overall claims experience for members and plans.

As part of this ongoing initiative, Blue Cross will continue to identify select high-cost drugs and will stop covering them when there are more cost-effective alternatives available for our commercial members.


FluMist® not covered for 2016-17 flu season

Effective Oct. 1, 2016, Blue Cross Blue Shield of Michigan is not covering the FluMist nasal spray vaccine for the 2016-17 flu season. The corresponding procedure codes are *90660 and *90672.

This decision is based on a recommendation from the Centers for Disease Control and Prevention. Data has shown that the nasal spray is less effective than flu shots in protecting against the flu.

We encourage our members to get an annual flu vaccination.


Michigan BAC and MPSERS members to participate in Medical Drug Prior Authorization Program

Beginning Jan. 1, 2017, members of the Michigan Bricklayers and Allied Crafts Health Care Fund, or Michigan BAC, and the Michigan Public School Employees Retirement System, or MPSERS, will participate in the Medical Drug Prior Authorization Program.

This program does not apply to Medicare, Medicare Advantage or Federal Employee Program® members.

The chart below lists the medications that are part of the Medical Drug Prior Authorization Program.

Drug names

Actemra®

Depo®-Testosterone

Kalbitor®

Signifor® LAR

Acthar® gel

Dysport®

Kanuma™

Simponi Aria®

Adagen®

Elaprase®

Krystexxa®

Soliris®

Aldurazyme®

Elelyso™

Lemtrada™

Stelara®

Aralast NP™

Entyvio™

Lumizyme®

Stelara IV®

Aveed®

Fabrazyme®

Makena®

Synagis®

Benlysta®

Firazyr®

Myobloc®

Testopel®

Berinert®

Flebogamma® DIF

Myozyme®

Tysabri®

Bivigam™

Gammagard Liquid®

Naglazyme®

Vimizim™

Botox®

Gammagard® S/D

Nplate®

Vpriv®

Carimune® NF

Gammaked®

Nucala®

Xeomin®

Cerezyme®

Gammaplex®

Octagam®

Xgeva®

Cimzia®

Gamunex®

Orencia®

Xiaflex®

Cinqair®

Glassia™

Privigen®

Xolair®

Cinryze®

Hizentra®

Probuphine®

Zemaira®

Cosentyx™

HyQvia®

Prolastin®-C

Cuvitru®

Ilaris®

Prolia®

Delatestryl®

Immune globulin

Ruconest®


Auto Groups

Process for obtaining certain specialty drugs changes for URMBT non-Medicare members

Effective Jan. 1, 2017, non-Medicare members who are part of the UAW Retiree Medical Benefits Trust will be required to obtain certain specialty medications through Accredo, an Express Scripts specialty pharmacy, under their prescription drug benefit for the drugs to be covered. This change affects URMBT Ford, URMBT GM and URMBT Chrysler PPO and Traditional Care Network non-Medicare members.

Previously, regardless of where they were obtained, certain specialty medications may have been covered under these members’ medical plan. As of Jan. 1, 2017, these specialty medications, when obtained in the outpatient setting, will only be covered under the member’s prescription drug benefit through Accredo. If members don’t order from Accredo, they’ll be responsible for the cost.

For dates of service on or after Jan. 1, 2017, there will be a coverage review for an initial specialty medication claim submitted under the medical plan. However, subsequent submissions under the medical plan will be rejected, with instructions to the provider to submit the medication under the patient’s prescription benefit plan through Accredo. The places of service may include the home, doctor’s office or outpatient settings.

Provider reimbursement for drug administration and supplies associated with the drug administration will continue through the patient’s medical benefit.

To obtain the list of specialty medications included in this change or to submit a prescription for specialty medications on behalf of URMBT members, contact Accredo at 1-800-987-4904 or fax new prescriptions to Accredo at 1-800-391-9707.


Medicare Advantage

Dose limits for Medicare members’ opioid prescriptions to take effect Jan. 1

The Centers for Medicare & Medicaid Services continues to combat the epidemic of prescription opioid abuse in the U.S. As a result, Blue Cross Blue Shield of Michigan and Blue Care Network will be required to establish a dose limitation for opioid drugs prescribed to our Medicare members. This change takes effect Jan. 1, 2017.

Safety limits for prescribed opioids
All Medicare prescription drug claims that include opioids and exceed a daily morphine equivalent dose of 250 mg will require a prior authorization before they may be dispensed at a pharmacy.

Blue Cross and BCN will calculate the daily morphine equivalent dose for each given Medicare member. We may deny an opioid prescription claim if the member’s cumulative morphine equivalent dose exceeds 250 mg across all of their claims. This daily cumulative morphine equivalent dose will be calculated using a Medicare member’s history of opioid prescription claims within our system.

Any opioid prescription claim or claims exceeding the 250 mg limit will require a prior authorization and clinical review by Blue Cross or BCN before the claims are covered at a pharmacy.

Known exceptions
CMS allows Medicare patients in certain situations to be excluded from this policy. Here are identified situations that are known exceptions from the daily morphine equivalent dose calculation:

  • Hospice care
  • Diagnoses or drug utilization history indicative of cancer
  • Reasonable overlapping dispensing rates for prescription refills or new prescription orders for continuing fills
  • Opioid usage previously determined by Blue Cross or BCN to be medically necessary through prior coverage determinations, prior authorization, pharmacy case management or appeals processes.

Prior authorization
Doctors who write prescriptions that exceed the safety limit must submit their prescriptions for a prior authorization. The prior authorization can be submitted by the doctor or his or her delegate. Please note:

  • Documentation of medical necessity and acknowledgement of the significant clinical circumstance must be submitted to Blue Cross or BCN for a clinical review.
  • The prescriber must demonstrate that the warranted amount of the opioid medication is needed to adequately manage the patient’s pain while being safe and appropriate.

For prior authorization, call our Clinical Help Desk at 1-800-437-3803 from 8 a.m. to 6 p.m. Monday through Friday.


Preauthorization for Medicare Advantage PPO outpatient PT and OT coming in January

As communicated in the September and October issues of The Record, Blue Cross Blue Shield of Michigan, in partnership with eviCore healthcare, is expanding its physical therapy use management program to include a preauthorization component.

Effective Jan. 1, 2017, outpatient physical and occupational therapy services for Blue Cross Medicare Plus BlueSM members who reside in Michigan will require preauthorization. Preauthorization will be based on category assignments that are determined by 12 months of independent PT and outpatient PT claims data (both MAPPO and commercial PPO data). For details on category assignments, see the September Record.

eviCore will mail letters to providers of PT and OT services, identifying their category assignments, by mid-November. If you don’t receive a letter, contact eviCore Customer Service at 1-877-917- BLUE (2583).

Training opportunities
Blue Cross will host two seminars on the program expansion at the Lyon Meadows Conference Center on Nov. 7, 2016. A webinar of the seminars will be made available.

In addition, interactive webinars will be held throughout November and early December. The webinars will provide more detailed information about preauthorization requirements in relation to your category assignment. See the October Record for registration information.

Preauthorization
Beginning Dec. 19, 2016, you can request prior authorization online and locate the clinical worksheets and CPT code list for outpatient physical and occupational therapy services by logging in to web-DENIS.

  • Click on Prior authorization.
  • Enter the NPI and contract number.
  • Select the service for which you are requesting prior authorization.
  • Click “OK” to be redirected to the eviCore healthcare web portal and proceed with authorization.

Requests for preauthorization can also be submitted by phone at 1-877-917- BLUE (2583) or by fax at 855-774-1319, but the fastest way to obtain authorizations is online. If a prior authorization isn’t obtained for these services, claims will be denied and the provider will be responsible for the costs.

For more information
The eviCore implementation website** provides additional information, including fax forms, national guidelines, Frequently Asked Questions, Quick Reference Guide and webinar details.

** Blue Cross Blue Shield of Michigan does not own or control this website.

No portion of this publication may be copied without the express written permission of Blue Cross Blue Shield of Michigan, except that BCBSM participating health care providers may make copies for their personal use. In no event may any portion of this publication be copied or reprinted and used for commercial purposes by any party other than BCBSM.

*CPT codes, descriptions and two-digit numeric modifiers only are copyright 2015 American Medical Association. All rights reserved.